CBD shows promise for severe epilepsy but faces challenges with drug interactions and inconsistent absorption
A review found that randomized controlled trials support CBD's efficacy in Dravet and Lennox-Gastaut syndromes, but complex pharmacokinetics, variable bioavailability, and significant drug interactions complicate its clinical use.
Quick Facts
What This Study Found
The authors reviewed the rapidly evolving field of cannabinoids for epilepsy, noting several important developments and remaining challenges.
Recent randomized placebo-controlled trials confirmed CBD's efficacy in two severe childhood epilepsy syndromes: Dravet syndrome and Lennox-Gastaut syndrome. This represented a major advance from the earlier era of anecdotal reports.
However, the review highlighted significant practical challenges. Cannabinoids appear to work through mechanisms other than the endogenous cannabinoid receptors CB1 and CB2, and the exact mechanism of antiseizure activity remains unclear. The pharmacokinetics are complex, with variable bioavailability making it difficult to develop consistent oral formulations.
Drug interactions represent a major complication for everyday use, particularly since epilepsy patients typically take multiple antiseizure medications. The review noted that further placebo-controlled studies were underway testing cannabidivarin (CBDV) in adults with focal epilepsy, potentially expanding the range of epilepsy types that might respond to cannabinoid treatment.
Key Numbers
Randomized trials confirmed efficacy in Dravet and Lennox-Gastaut syndromes. Cannabidivarin trials underway for adult focal epilepsy. Two endogenous cannabinoid receptors (CB1, CB2) do not appear to mediate the antiseizure effect.
How They Did This
This was a narrative review of the current state of cannabinoid research in epilepsy, covering mechanisms of action, pharmacokinetics, clinical trial evidence, drug interactions, and ongoing research.
Why This Research Matters
As CBD-based epilepsy treatments move from clinical trials to clinical practice, understanding the practical challenges is crucial for patients and clinicians. The drug interaction profile is particularly important because poorly managed interactions could paradoxically worsen seizure control or cause toxicity from co-administered medications.
The Bigger Picture
The cannabinoid-epilepsy story represents one of the most successful translations from patient advocacy and anecdotal evidence to rigorous clinical trials and FDA approval. The remaining challenges, especially around drug interactions and mechanisms of action, are now the focus of the next phase of research.
What This Study Doesn't Tell Us
This is a brief narrative review rather than a systematic review. The evidence at the time was strongest for two severe childhood epilepsies, and generalizability to other epilepsy types was uncertain. Drug interaction data were still accumulating. Long-term safety data were limited.
Questions This Raises
- ?How exactly does CBD prevent seizures if not through cannabinoid receptors?
- ?Can the drug interaction challenges be managed well enough for routine clinical use?
- ?Will cannabidivarin prove effective for the much larger population of adults with focal epilepsy?
Trust & Context
- Key Stat:
- CBD proven effective for Dravet and Lennox-Gastaut syndromes in randomized trials
- Evidence Grade:
- This review covers evidence from randomized controlled trials for specific syndromes, providing moderate overall evidence across the epilepsy field.
- Study Age:
- Published in 2018, around the time of Epidiolex FDA approval. Clinical experience with CBD in epilepsy has expanded significantly since.
- Original Title:
- Cannabinoids for epilepsy: What do we know and where do we go?
- Published In:
- Epilepsia, 59(2), 291-296 (2018)
- Authors:
- Brodie, Martin J, Ben-Menachem, Elinor
- Database ID:
- RTHC-01606
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does CBD stop seizures?
Randomized controlled trials have confirmed that CBD reduces seizures in two severe childhood epilepsy syndromes: Dravet syndrome and Lennox-Gastaut syndrome. Evidence for other types of epilepsy was still being gathered at the time of this review.
Can CBD interact with other seizure medications?
Yes, this is a significant concern. CBD interacts with many common antiseizure medications through shared liver enzyme pathways. These interactions can raise or lower blood levels of other medications, potentially affecting seizure control or causing side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01606APA
Brodie, Martin J; Ben-Menachem, Elinor. (2018). Cannabinoids for epilepsy: What do we know and where do we go?. Epilepsia, 59(2), 291-296. https://doi.org/10.1111/epi.13973
MLA
Brodie, Martin J, et al. "Cannabinoids for epilepsy: What do we know and where do we go?." Epilepsia, 2018. https://doi.org/10.1111/epi.13973
RethinkTHC
RethinkTHC Research Database. "Cannabinoids for epilepsy: What do we know and where do we g..." RTHC-01606. Retrieved from https://rethinkthc.com/research/brodie-2018-cannabinoids-for-epilepsy-what
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.